Table 2.
Clinical and epidemiological characteristics of adult male lymphoma survivors according to testosterone group, with subdivisions according to the availability of two sample, at diagnosis and follow-up [3]
| Survivors with “Low normal TT” (extended hormonal assessment) N 60 |
Survivors with “High normal TT” (no extended hormonal analysis) N 83 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 20 survivors with two samples (cryopreservation at diagnosis + VitalityCheck) | 40 with one sample (VitalityCheck) | 30 survivors with two samples (cryopreservation at diagnosis + VitalityObs) | 53 with one sample (VitalityObs) | |||||||
| Diagnosis | FU2 | FU2 | Diagnosis | FU1 | FU1 | |||||
| Median (perc) | Median (perc) | % change (CI) | Median (perc) | Mean diff between FU2 (CI) | Median (perc) | Median (perc) | % change (CI) | Median (perc) | Mean diff between FU1 (CI) | |
| Age, years | 28.0 (21.0–36.5) | 37.5 (27.9–49.6) | – | 55.0 (30.0–66.0) | 15.9* (9.5–19.1) | 26.0 (19.0–40.5) | 33.0 (26.5–48.1) | – | 55.0 (31.6–64.4) | 16.6* (12.7–20.6) |
| Follow-up, years | – | 9.5 (6.0–14.0) | – | 6.5 (4.0–11.0) | 1.3* (1.5–4.3) | – | 8.0 (4.0–13.0) | – | 6.0 (3.0–11.0) | 1.3 (− 0.2–2.6) |
| Treatment, N (%)a | ||||||||||
| ABVD | – | – | – | – | p < 0.002* | – | – | – | – | p = 0.02* |
| BEACOPP | ||||||||||
| CHOP | ||||||||||
| N of cycles | ||||||||||
| ABVD | 6.0 | – | 4.0 | p = 0.17 | 5.0 | 4.0 | p = 0.02* | |||
| BEACOPP | 6.0 | 6.0 | 6.0 | 8.0 | ||||||
| CHOP | 6.0 | 6.0 | 6.0 | 6.0 | ||||||
| TT, IA, nmol/l | 14.2 (8.1–21.3) | 10.6 (8.3–14.6) | 21.1%↓* (5.2–34.3) | 10.4 (6.8–16.3) | 0.4 (− 1.0–1.9) | 15.4 (11.3–28.9) | 18.0 (15.0–25.6) | 22.6%↑* (1.6–47.9) | 19.0 (15.0–25.0) | 0.4 (− 2.0–1.2) |
N, number; FU1, at VitalityObs; FU2, at VitalityCheck; TT, total testosterone; FT, free testosterone, SHBG, sexual hormone binding globulin; LH, luteinizing hormone; CI, 5–95% confidence interval; perc, 5–95% percentiles; FU1, follow-up 1; FU2, follow-up 2; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone.
See earlier published data for full overview of treatment regimens [3]
aAll treated with ABVD and BEACOPP were HL survivors; all treated with R-CHOP was DLBCL survivors.
*Statistically significant changes and differences.